The clinical effectiveness and cost-effectiveness of treatments for idiopathic pulmonary fibrosis: A systematic review and economic evaluation

Health Technology Assessment

Volumn 19, Issue 20, 2015, Pages 1-336

  Loveman, Emma ^a   Copley, Vicky R ^a   Colquitt, Jill ^a   Scott, David A ^b   Clegg, Andy ^a   Jones, Jeremy ^a   O’Reilly, Katherine Ma ^c   Singh, Sally ^d   Bausewein, Claudia ^e   Wells, Athol ^f  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b ICON PLC   (United Kingdom)

^c MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^d UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^e LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^f ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; NINTEDANIB; PIRFENIDONE; SILDENAFIL; THALIDOMIDE;

ARTICLE; CLINICAL EFFECTIVENESS; CONSENSUS; CONSERVATIVE TREATMENT; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; ECONOMIC EVALUATION; EVIDENCE BASED MEDICINE; FIBROSING ALVEOLITIS; HEALTH PROGRAM; HUMAN; META ANALYSIS; NATIONAL HEALTH SERVICE; PROBABILITY; PULMONARY REHABILITATION; QUALITY CONTROL; QUALITY OF LIFE; SENSITIVITY ANALYSIS; SOCIAL WORK; SURVIVAL; SYSTEMATIC REVIEW; UNIVARIATE ANALYSIS; ECONOMICS; IDIOPATHIC PULMONARY FIBROSIS; STATISTICAL MODEL; TREATMENT OUTCOME;

COST-BENEFIT ANALYSIS; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; MODELS, ECONOMIC; TREATMENT OUTCOME;

EID: 84925145655     PISSN: 13665278     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta19200     Document Type: Article

References (176)

1. Meltzer EB, Noble PW. Idiopathic pulmonary fibrosis. Orphanet J Rare Dis 2008;3:8. http://dx.doi.org/10.1186/1750-1172-3-8
2. du Bois RM. An earlier and more confident diagnosis of idiopathic pulmonary fibrosis. Eur Respir J 2012;21:141-6. http://dx.doi.org/10.1183/09059180.00000812
3. Guenther A, Korfei M, Mahavadi P, von der Beck D, Ruppert C, Markart P. Unravelling the progressive pathophysiology of idiopathic pulmonary fibrosis. Eur Respir J 2012;21:152-60. http://dx.doi.org/10.1183/09059180.00001012
4. Swigris JJ, Stewart AL, Gould MK, Wilson SR. Patients’ perspectives on how idiopathic pulmonary fibrosis affects the quality of their lives. Health Qual Life Outcomes 2005;3:61. http://dx.doi.org/10.1186/1477-7525-3-61
5. Dempsey OJ. Clinical review: idiopathic pulmonary fibrosis - past, present and future. Respir Med 2006;100:1871-85. http://dx.doi.org/10.1016/j.rmed.2006.08.017
6. Collard HR, Moore BB, Flaherty KR, Brown KK, Kaner RJ, King TE Jr, et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2007;176:636-43. http://dx.doi.org/10.1164/rccm.200703-463PP
7. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS) and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000;161:646-64. http://dx.doi.org/10.1164/ajrccm.161.2.ats3-00
8. American Thoracic Society. American Thoracic Society/European Respiratory Society International multidisciplinary consensus classification of idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2002;165:277-304.
9. Wells AU, Hirani N, on behalf of the BTS interstitial lung disease guideline group. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax 2008;63:v1-58. http://dx.doi.org/10.1136/thx.2008.101691
10. American Thoracic Society. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183:788-824. http://dx.doi.org/10.1164/rccm.2009-040GL
11. Gribbin J, Hubbard RB, Jeune IL, Smith CJ, West J, Tata LJ. Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax 2006;61:980-5. http://dx.doi.org/10.1136/thx.2006.062836
12. Mejía M, Carrillo G, Rojas-Serrano J, Estrada A, Suárez T, Alonso D, et al. Idiopathic pulmonary fibrosis and emphysema: decreased survival associated with severe pulmonary arterial hypertension. Chest 2009;136:10-15. http://dx.doi.org/10.1378/chest.08-2306
13. Navaratnam V, Fleming KM, West J, Smith CJ, Jenkins RG, Fogarty A, et al. The rising incidence of idiopathic pulmonary fibrosis in the U.K. Thorax 2011;66:462-7. http://dx.doi.org/10.1136/thx.2010.148031
14. Fernández Pérez ER, Daniels CE, Schroeder DR, St. Sauver J, Hartman TE, Bartholmai BJ, et al. Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: a population-based study. Chest 2010;137:129-37. http://dx.doi.org/10.1378/chest.09-1002
15. Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006;174:810-6. http://dx.doi.org/10.1164/rccm.200602-163OC
16. Costabel U. Idiopathic pulmonary fibrosis: recent milestones in disease management. Eur Respir J 2012;21:140. http://dx.doi.org/10.1183/09059180.00000712
17. Song JW, Hong SB, Lim CM, Koh Y, Kim DS. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J 2011;37:356-63. http://dx.doi.org/10.1183/09031936.00159709
18. Cottin V. Changing the idiopathic pulmonary fibrosis treatment approach and improving patient outcomes. Eur Respir J 2012;21:161-7. http://dx.doi.org/10.1183/09059180.00001112
19. Agarwal R, Jindal SK. Acute exacerbation of idiopathic pulmonary fibrosis: a systematic review. Eur J Intern Med 2008;19:227-35. http://dx.doi.org/10.1016/j.ejim.2007.04.024
20. Mura M, Zompatori M, Pacilli AM, Fasano L, Schiavina M, Fabbri M. The presence of emphysema further impairs physiologic function in patients with idiopathic pulmonary fibrosis. Respir Care 2006;51:257-65.
21. Nathan SD, Noble PW, Tuder RM. Idiopathic pulmonary fibrosis and pulmonary hypertension: connecting the dots. Am J Respir Crit Care Med 2007;175:875-80. http://dx.doi.org/10.1164/rccm.200608-1153CC
22. Nathan SD, Shlobin OA, Weir N, Ahmad S, Kaldjob JM, Battle E, et al. Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium. Chest 2011;140:221-9. http://dx.doi.org/10.1378/chest.10-2572
23. National Institute for Health and Care Excellence. Pirfenidone for Treating Idiopathic Pulmonary Fibrosis. Technology appraisal TA282. London: NICE; 2013.
24. Bajwah S, Higginson IJ, Ross JR, Wells AU, Birring SS, Patel A, et al. Specialist palliative care is more than drugs: a retrospective study of ILD patients. Lung 2012;190:215-20. http://dx.doi.org/10.1007/s00408-011-9355-7
25. Clark M, Cooper B, Singh S, Cooper M, Carr A, Hubbard R. A survey of nocturnal hypoxaemia and health related quality of life in patients with cryptogenic fibrosing alveolitis. Thorax 2001;56:482-6. http://dx.doi.org/10.1136/thorax.56.6.482
26. Ryerson CJ, Donesky D, Pantilat SZ, Collar, Collard HR. Dyspnea in idiopathic pulmonary fibrosis: a systematic review. J Pain Symptom Manage 2012;43:771-82. http://dx.doi.org/10.1016/j.jpainsymman.2011.04.026
27. Lewis D, Scullion J. Palliative and end-of-life care for patients with idiopathic pulmonary fibrosis: challenges and dilemmas. Int J Palliat Nurs 2012;18:331-7. http://dx.doi.org/10.12968/ijpn.2012.18.7.331
28. Booth S, Bausewein C, Higginson IJ, Moosavi SH. Pharmacological treatment of refractory breathlessness. Expert Rev Respir Med 2009;3:21-36. http://dx.doi.org/10.1586/17476348.3.1.21
29. Martinez FJ, Safrin S, Weycker D, Starko KM, Bradford WZ, King TE Jr, et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med 2005;142:963-7. http://dx.doi.org/10.7326/0003-4819-142-12_Part_1-200506210-00005
30. Health and Social Care Information Centre. Hospital Episode Statistics: Inpatient Data, Main Procedures and Interventions. London: Health and Social Care Information Centre; 2009. URL: www.hesonline.nhs.uk/Ease/servlet/ContentServer?siteID=1937&categoryID=192 (accessed 14 June 2013).
31. National Institute for Health and Care Excellence. Diagnosis and Management of Suspected Idiopathic Pulmonary Fibrosis. Clinical guideline CG163. London: NICE; 2013.
32. Spagnolo P, Tonelli R, Cocconcelli E, Stefani A, Richeldi L. Idiopathic pulmonary fibrosis: diagnostic pitfalls and therapeutic challenges. Multidiscip Respir Med 2012;7:42. http://dx.doi.org/10.1186/2049-6958-7-42
33. Cottin V, Cordier JF. Velcro crackles: the key for early diagnosis of idiopathic pulmonary fibrosis? Eur Respir J 2012;40:519-21. http://dx.doi.org/10.1183/09031936.00001612
34. Lamas DL, Kawut SM, Bagiella E, Phillip N, Arcasoy SM. Delayed access and survival in idiopathic pulmonary fibrosis. A cohort study. Am J Respir Crit Care Med 2011;184:842-7. http://dx.doi.org/10.1164/rccm.201104-0668OC
35. Collard HR, Tino G, Noble PW, Shreve MA, Michaels M, Carlson B, et al. Patient experiences with pulmonary fibrosis. Respir Med 2007;101:1350-54. http://dx.doi.org/10.1016/j.rmed.2006.10.002
36. Schoenheit G, Becattelli I, Cohen AH. Living with idiopathic pulmonary fibrosis: an in-depth qualitative survey of European patients. Chron Respir Dis 2011;8:225-31. http://dx.doi.org/10.1177/1479972311416382
37. Lacasse Y, Goldstein R, Lasserson T, J Martin. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006;4:CD003793.
38. Christie JD, Edwards LB, Kucheryavaya AY, Benden C, Dipchand AI, Dobbels F, et al. The Registry of the International Society for Heart and Lung Transplantation: 29th official adult heart transplant report 2012. J Heart Lung Transplant 2013;31:1073. http://dx.doi.org/10.1016/j.healun.2012.08.004
39. George TJ, Arnaoutakis GJ, Shah AS. Lung transplant in idiopathic pulmonary fibrosis. Arch Surg 2011;146:1204-9. http://dx.doi.org/10.1001/archsurg.2011.239
40. Kilic A, Merlo CA, Conte J, Shah. Lung transplantation in patients 70 years old or older: have outcomes changed after implementation of the lung allocation score? J Thorac Cardiovasc Surg 2012;144:1133-8. http://dx.doi.org/10.1016/j.jtcvs.2012.07.080
41. Orens JB, Estenne M, Arcasoy S, Conte JV, Corris P, Egan JJ, et al. International guidelines for the selection of lung transplant candidates: 2006 update-a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006;25:745-55. http://dx.doi.org/10.1016/j.healun.2006.03.011
42. Allen JG, Arnaoutakis GJ, Weiss ES, Merlo CA, Conte JV, Shah AS. The impact of recipient body mass index on survival after lung transplantation. J Heart Lung Transplant 2010;29:1026-33. http://dx.doi.org/10.1016/j.healun.2010.05.005
43. Kazerooni EA, Martinez FJ, Flint A, Jamadar DA, Gross BH, Spizarny DL, et al. Thin-section CT obtained at 10-mm increments versus limited three-level thin-section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring. Am J Roentgenol 1997;169:977-83. http://dx.doi.org/10.2214/ajr.169.4.9308447
44. Thabut G, Mal H, Castier Y, Groussard O, Brugiere O, Marrash-Chahla R, et al. Survival benefit of lung transplantation for patients with idiopathic pulmonary fibrosis. J Thorac Cardiovasc Surg 2003;126:469-75. http://dx.doi.org/10.1016/S0022-5223(03)00600-7
45. Mason DP, Brizzio ME, Alster JM, McNeill AM, Murthy SC, Budev MM, et al. Lung transplantation for idiopathic pulmonary fibrosis. Ann Thorac Surg 2013;84:1121-8. http://dx.doi.org/10.1016/j.athoracsur.2007.04.096
46. Grossman RF, Frost A, Zamel N, Patterson GA, Cooper JD, Myron PR, et al. Results of single-lung transplantation for bilateral pulmonary fibrosis. The Toronto Lung Transplant Group. NEJM 1990;322:727-33. http://dx.doi.org/10.1056/NEJM199003153221104
47. De Oliveira NC, Osaki S, Maloney J, Cornwell RD, Meyer KC. Lung transplant for interstitial lung disease: outcomes for single versus bilateral lung transplantation. Interact Cardiovasc Thorac Surg 2012;14:263-7. http://dx.doi.org/10.1093/icvts/ivr085
48. Lanken PN, Terry PB, DeLisser HM, Fahy BF, Hansen-Flaschen J, Heffner JE, et al. An official American Thoracic Society clinical policy statement: palliative care for patients with respiratory diseases and critical illnesses. Am J Respir Crit Care Med 2008;177:912-27. http://dx.doi.org/10.1164/rccm.200605-587ST
49. Lee JS, McLaughlin S, Collard HR. Comprehensive care of the patient with idiopathic pulmonary fibrosis. Curr Opin Pulm Med 2011;17:384-54. http://dx.doi.org/10.1097/MCP.0b013e328349721b
50. Bradley B, Branley HM, Egan JJ, Greaves MS, Hansell DM, Harrison NK, et al. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax 2008;63:1-58. http://dx.doi.org/10.1136/thx.2008.101691
51. Jones PW, Quirk FH, Baveystock CM. The St George’s Respiratory Questionnaire. Respir Med 1991;85:25-31. http://dx.doi.org/10.1016/S0954-6111(06)80166-6
52. Williams JE, Singh SJ, Sewell L, Guyatt GH, Morgan MD. Development of a self-reported Chronic Respiratory Questionnaire (CRQ-SR). Thorax 2001;56:954-59. http://dx.doi.org/10.1136/thorax.56.12.954
53. American Thoracic Society. ATS Statement: guideline for the six-minute walk test. Am J Respir Crit Care Med 2002;166:111-17. http://dx.doi.org/10.1164/ajrccm.166.1.at1102
54. Singh SJ, Morgan MD, Scott S, Walters D, Hardman AE. Development of a shuttle walking test of disability in patients with chronic airways obstruction. Thorax 1992;47:1019-24. http://dx.doi.org/10.1136/thx.47.12.1019
55. Horton MR, Santopietro V, Matthew L, Horton KM, Polito AJ, Liu MC, et al. Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis. Ann Intern Med 2012;157:398-406. http://dx.doi.org/10.7326/0003-4819-157-6-201209180-00003
56. European Medicines Agency. Public Summary of Opinion on Orphan Designation: Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis. London: European Medicines Agency, Committee for Orphan Medicinal Products; 2013. URL: www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2013/05/WC500143247.pdf (accessed 20 May 2013).
57. Centre for Reviews and Dissemination. Systematic Reviews: CRD’s Guidance for Undertaking Reviews in Health Care. 3rd edn. York: CRD, University of York; 2009.
58. Higgins JP, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0 (updated March 2011). London: The Cochranes; 2011. URL: www.cochrane- handbook.org (accessed 14 June 2013).
59. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ 1996;313:275-83. http://dx.doi.org/10.1136/bmj.313.7052.275
60. Philips Z, Ginnelly L, Sculpher M, Claxton K, Golder S, Riemsma R, et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess 2004;8(36). http://dx.doi.org/10.3310/hta8360
61. Jastrzebski D, Kozielski J, Zebrowska A. [Pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis with inspiratory muscle training.] Pneumonologia i Alergologia Polska 2008;76:131-41.
62. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011;377:1760-9. http://dx.doi.org/10.1016/S0140-6736(11)60405-4
63. Dowman L, McDonald CF, Hill C, Lee A, Barker K, Boote C, et al. The benefits of exercise training in interstitial lung disease: protocol for a multicentre randomised controlled trial. BMC Pulm Med 2013;13:8. http://dx.doi.org/10.1186/1471-2466-13-8
64. Gomez O, Ramos CF, Cardenas D, Gaunaurd I, Eustis N, Cohen M, et al. Exercise training during pulmonary rehabilitation increases activity levels of IPF patients. Am J Respir Crit Care Med 2012;185:A4885.
65. Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010;35:821-9. http://dx.doi.org/10.1183/09031936.00005209
66. Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005;171:1040-7. http://dx.doi.org/10.1164/rccm.200404-571OC
67. Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005;353:2229-42. http://dx.doi.org/10.1056/NEJMoa042976
68. Raghu G, Anstrom KJ, King J, Lasky JA, Martinez FJ. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012;366:1968-77. http://dx.doi.org/10.1056/NEJMoa1113354
69. Homma S, Azuma A, Taniguchi H, Ogura T, Mochiduki Y, Sugiyama Y, et al. Efficacy of inhaled N-acetylcysteine monotherapy in patients with early stage idiopathic pulmonary fibrosis. Respirology 2012;17:467-77. http://dx.doi.org/10.1111/j.1440-1843.2012.02132.x
70. Raghu G, Depaso WJ, Cain K, Hammar SP, Wetzel CE, Dreis DF, et al. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. Am Rev Respir Dis 1991;144:291-6. http://dx.doi.org/10.1164/ajrccm/144.2.291
71. Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011;365:1079-87. http://dx.doi.org/10.1056/NEJMoa1103690
72. Zisman DA, Schwarz M, Anstrom KJ, Collard HR, Flaherty KR, Hunninghake GW. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med 2010;363:620-8. http://dx.doi.org/10.1056/NEJMoa1002110
73. Nishiyama O, Kondoh Y, Kimura T, Kato K, Kataoka K, Ogawa T, et al. Effects of pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis. Respirology 2008;13:394-9. http://dx.doi.org/10.1111/j.1440-1843.2007.01205.x
74. Lindell KO, Olshansky E, Song MK, Zullo TG, Gibson KF, Kaminski N, et al. Impact of a disease-management program on symptom burden and health-related quality of life in patients with idiopathic pulmonary fibrosis and their care partners. Heart Lung 2010;39:304-13. http://dx.doi.org/10.1016/j.hrtlng.2009.08.005
75. Horton MR, Santopeitro V, Matthew L, Richardson B, Danoff SK, Polito AJ. Thalidomide suppresses cough and improves quality of life in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012;185:A3635.
76. Caldwell D, Ades AE, Higgins JPT. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 2005;331:897-900. http://dx.doi.org/10.1136/bmj.331.7521.897
77. Hasselblad V. Meta-analysis of multitreatment studies. Med Decis Making 1998;18:37-43. http://dx.doi.org/10.1177/0272989X9801800110
78. National Institute for Health and Clinical Excellenece. Guide to the Methods of Technology Appraisal. London: NICE; 2004.
79. Hoaglin DC, Hawkins N, Jansen JP, Scott DA, Itzler R, Cappalleri JC, et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on indirect treatment comparisons good research practices - part 2. Value Health 2011;14:429-37. http://dx.doi.org/10.1016/j.jval.2011.01.011
80. Albera C. Challenges in idiopathic pulmonary fibrosis trials: the point on end-points. Eur Respir Rev 2011;20:195-200. http://dx.doi.org/10.1183/09059180.00001711
81. Salanti G, Higgins JPT, Ades AE, Ioannidis JPA. Evaluation of networks of randomized trials. Stat Methods Med Res 2008;17:279-301. http://dx.doi.org/10.1177/0962280207080643
82. Egger M, Davey Smith G, Altman DG. Systematic Reviews in Health Care: Meta-Analysis in Context. London: BMJ Books; 2001. http://dx.doi.org/10.1002/9780470693926
83. Dias S, Welton NJ, Sutton AJ, Ades AE. NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta-Analysis of Randomised Controlled Trials 2011. URL: www.nicedsu.org.uk (accessed 14 June 2013).
84. Spiegelhalter DJ, Best NG, Carlin BP, van der Linde A. Bayesian measures of model complexity and fit. J R Stat Soc Ser B 2002;64:583-639. http://dx.doi.org/10.1111/1467-9868.00353
85. Brooks SP, Gelman A. General methods for monitoring convergence of iterative simulations. J Comput Graph Stat 1998;7:434-55.
86. Higgins JPT, Thompson SG, Spiegelhalter DJ. A re-evaluation of random-effects meta-analysis. J R Stat Soc Ser A 2009;172:137-59.http://dx.doi.org/10.1111/j.1467-985X.2008.00552.x
87. Chinn S. A simple method for converting an odds ratio to effect size for use in meta-analysis. Stat Med 2000;19:3127-31. http://dx.doi.org/10.1002/1097-0258(20001130)19:22<3127::AID-SIM784>3.0.CO;2-M
88. Dias S, Welton NJ, Sutton AJ, Caldwell D, Lu G, Ades AE. Evidence synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials. Med Decis Making 2013;33:641-56. http://dx.doi.org/10.1177/0272989X12455847
89. Bucher AC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomised controlled trials. J Clin Epidemiol 1997;50:683-90. http://dx.doi.org/10.1016/S0895-4356(97)00049-8
90. Dias S, Welton NJ, Caldwell D, Ades AE. Checking consistency in mixed treatment comparison meta-analysis. Stat Med 2010;29:932-44. http://dx.doi.org/10.1002/sim.3767
91. Dequen P, Sutton AJ, Scott DA, Abrams KR. Searching for indirect evidence and extending the network of studies for network meta-analysis: case study in venous thromboembolic events prevention following elective total knee replacement surgery. Value Health 2014;17:416-23. http://dx.doi.org/10.1016/j.jval.2014.02.013
92. Krahn U, Binder H, König J. A graphical tool for locating inconsistency in network meta-analyses. BMC Med Res Methodol 2013;13:35. http://dx.doi.org/10.1186/1471-2288-13-35
93. Cox DR, Snell EJ. Analysis of Binary Data. London: Chapman & Hall; 1989.
94. Spagnolo P, Del GC, Luppi F, Cerri S, Balduzzi S, Walters EH, et al. Non-steroid agents for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev 2010;9:CD003134. http://dx.doi.org/doi:10.1002/14651858.CD003134.pub2
95. Richeldi L, Davies HR, Ferrara G, Franco F. Corticosteroids for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev 2003;3:CD002880.
96. Bajwa EK, Ayas NT, Schulzer M, Mak E, Ryu JH, Malhotra A. Interferon-gamma1b therapy in idiopathic pulmonary fibrosis: a meta-analysis. Chest 2005;128:203-6. http://dx.doi.org/10.1378/chest.128.1.203
97. King TE Jr, Albera C, du Bois RM, Bradford W, Costabel U, Noble PW, et al. The effect of treatment with pirfenidone on longitudinal change In lung volume in patients with idiopathic pulmonary fibrosis (IPF): a meta-analysis of outcomes in four randomized controlled clinical trials. Am J Respir Crit Care Med 2011;183:A5302.
98. Ryerson CJ, Donesky DA, Pantilat SZ, Collard HR. Dyspnea in idiopathic pulmonary fibrosis: a systematic review. J Pain Symptom Manage 2012;43:771-82. http://dx.doi.org/10.1016/j.jpainsymman.2011.04.026
99. Hagaman JT, Kinder BW, Eckman MH. Thiopurine S-methyltranferase testing in idiopathic pulmonary fibrosis: a pharmacogenetic cost-effectiveness analysis. Lung 2010;188:125-32. http://dx.doi.org/10.1007/s00408-009-9217-8
100. Cooper K, Mendes D, Picot J, Loveman E. Pirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis: A Single Technology Appraisal. SHTAC; 2012. URL: www.nice.org.uk/guidance/ta282/documents/idiopathic-pulmonary-fibrosis-pirfenidone-evidence-review-group-report2(accessed 1 December 2014).
101. Gisbert JP, Gomollon F, Cara C, Luna M, González-Lama Y, Pajares JM, et al. Thioprine methyltransferase activity in Spain: a study of 14,545 patients. Dig Dis Sci 2007;52:1262-9. http://dx.doi.org/10.1007/s10620-006-9119-z
102. Schwab M, Schaffeler E, Marx C, Fischer C, Lang T, Behrens C, et al. Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. Pharmacogenetics 2002;12:429-36. http://dx.doi.org/10.1097/00008571-200208000-00003
103. Ansari A, Hassan C, Duley J, Marinaki A, Shobowale-Bakre EM, Seed P, et al. Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease. Aliment Pharmacol Ther 2002;16:1743-50. http://dx.doi.org/10.1046/j.1365-2036.2002.01353.x
104. Perri D, Cole DE, Friedman O, Piliotis E, Mintz S, Adhikari NK. Azathioprine and diffuse alveolar haemorrhage: the pharmacogenetics of thiopurine methyltransferase. Eur Respir J 2007;30:1014-7. http://dx.doi.org/10.1183/09031936.00026107
105. Meggitt SJ, Reynolds NJ. Azathioprine for atopic dermatitis. Clin Exp Dermatol 2001;26:369-75. http://dx.doi.org/10.1046/j.1365-2230.2001.00837.x
106. Yorke J, Jones PW, Swigris JJ. Development and validity testing of an IPF-specific version of the St George’s Respiratory Questionnaire. Thorax 2010;65:921-6. http://dx.doi.org/10.1136/thx. 2010.139121
107. Swigris J, Wilson SR, Green KE, Sprunger DB, Brown KK, Wamboldt FS. Development of the ATAQ-IPF: a tool to assess quality of life in IPF. Health Qual Life Outcomes 2010;8:77. http://dx.doi.org/10.1186/1477-7525-8-77
108. Patel AS, Siegert R, Brignall K, Gordon P, Steer S, Desai SR, et al. The development and validation of the King’s Brief Interstitial Lung Disease (K-BILD) health status questionnaire. Thorax 2012;67:804-10. http://dx.doi.org/10.1136/thoraxjnl-2012-201581
109. Martinez TY, Pereira CA, dos Santos ML, Ciconelli RM, Guimarães SM, Martinez JA. Evaluation of the short-form 36-item questionnaire to measure health-related quality of life in patients with idiopathic pulmonary fibrosis. Chest 2000;117:1627-32. http://dx.doi.org/10.1378/chest.117.6.1627
110. Ozalevli S, Karaali HK, Ilgin D, Ucan ES. Effect of home-based pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis. Multidiscip Respir Med 2010;5:31-7. http://dx.doi.org/10.1186/2049-6958-5-1-31
111. Baddini Martinez JA, Martinez TY, Lovetro Galhardo FP, de Castro Pereira CA. Dyspnea scales as a measure of health-related quality of life in patients with idiopathic pulmonary fibrosis. Med Sci Monit 2002;8:CR405-10.
112. Jastrzebski D, Kozielski J, Banas A, Cebula T, Gumola A, Ziora D, et al. Quality of life during one-year observation of patients with idiopathic pulmonary fibrosis awaiting lung transplantation. J Physiol Pharmacol 2005;56(Suppl. 4):99-105.
113. Kozu R, Jenkins S, Senjyu H. Effect of disability level on response to pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis. Respirology 2011;16:1196-202. http://dx.doi.org/10.1111/j.1440-1843.2011.02029.x
114. Kozu R, Senjyu H, Jenkins SC, Mukae H, Sakamoto N, Kohno S. Differences in response to pulmonary rehabilitation in idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease. Respiration 2011;81:196-205. http://dx.doi.org/10.1159/000315475
115. Tomioka H, Imanaka K, Hashimoto K, Iwasaki H. Health-related quality of life in patients with idiopathic pulmonary fibrosis-cross-sectional and longitudinal study. Intern Med 2007;46:1533-42. http://dx.doi.org/10.2169/internalmedicine.46.6218
116. Mermigkis C, Bouloukaki I, Antoniou KM, Mermigkis D, Psathakis K, Giannarakis I, et al. CPAP therapy in patients with idiopathic pulmonary fibrosis and obstructive sleep apnea: does it offer a better quality of life and sleep? Sleep Breath 2013;17:1137-43. http://dx.doi.org/10.1007/s11325-013-0813-8
117. De Vries J, Seebregts A, Drent M. Assessing health status and quality of life in idiopathic pulmonary fibrosis: which measure should be used? Respir Med 2000;94:273-8. http://dx.doi.org/10.1053/rmed.1999.0736
118. Peng S, Li Z, Kang J, Hou X. Cross-sectional and longitudinal construct validity of the Saint George’s Respiratory Questionnaire in patients with IPF. Respirology 2008;13:871-9. http://dx.doi.org/10.1111/j.1440-1843.2008.01359.x
119. Nishiyama O, Taniguchi H, Kondoh Y, Kimura T, Ogawa T, Watanabe F, et al. Health-related quality of life in patients with idiopathic pulmonary fibrosis. What is the main contributing factor? Respir Med 2005;99:408-14. http://dx.doi.org/10.1016/j.rmed.2004.09.005
120. Tzanakis N, Samiou M, Lambiri I, Antoniou K, Siafakas N, Bouros D. Evaluation of health-related quality-of-life and dyspnea scales in patients with idiopathic pulmonary fibrosis. Correlation with pulmonary function tests. Eur J Intern Med 2005;16:105-12. http://dx.doi.org/10.1016/j.ejim.2004.09.013
121. Lechtzin N, Hilliard ME, Horton MR. Validation of the Cough Quality-of-Life Questionnaire in patients with idiopathic pulmonary fibrosis. Chest 2013;143:1745-9. http://dx.doi.org/10.1378/chest.12-2870
122. Nishiyama O, Taniguchi H, Kondoh Y, Kimura T, Kataoka K, Nishimura K, et al. Health-related quality of life does not predict mortality in idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 2012;29:113-18.
123. Verma G, Marras T, Chowdhury N, Singer L. Health-related quality of life and 6 min walk distance in patients with idiopathic pulmonary fibrosis. Can Respir J 2011;18:283-7.
124. Zimmermann CS, Carvalho CR, Silveira KR, Yamaguti WP, Moderno EV, Salge JM, et al. Comparison of two questionnaires which measure the health-related quality of life of idiopathic pulmonary fibrosis patients. Braz J Med Biol Res 2007;40:179-87. http://dx.doi.org/10.1590/S0100-879X2007000200004
125. Raghu G, King TE Jr., Behr J, Brown KK, du Bois RM, Leconte I, et al. Quality of life and dyspnoea in patients treated with bosentan for idiopathic pulmonary fibrosis (BUILD-1). Eur Respir J 2010;35:118-23. http://dx.doi.org/10.1183/09031936.00188108
126. Swigris JJ, Brown KK, Behr J, du Bois RM, King TE, Raghu G, et al. The SF-36 and SGRQ: validity and first look at minimum important differences in IPF. Respir Med 2010;104:296-304. http://dx.doi.org/10.1016/j.rmed.2009.09.006
127. Lutogniewska W, Jastrzebski D, Wyrwol J, Ksiazek B, Ochman M, Kowalski K, et al. Dyspnea and quality of life in patients referred for lung transplantation. Eur J Med Res 2010;15(Suppl. 2):76-8.
128. King J, Behr J, Brown KK, du Bois RM, Lancaster L, de Andrade JA, et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008;177:75-81. http://dx.doi.org/10.1164/rccm.200705-732OC
129. Huang IC, Willke RJ, Atkinson MJ, Lenderking WR, Frangakis C, Wu AW. US and UK versions of the EQ-5D preference weights: does choice of preference weights make a difference? Qual Life Res 2007;16:1065-72. http://dx.doi.org/10.1007/s11136-007-9206-4
130. Cheung K, Oemar M, Oppe M, Rabin R. EQ-5D User Guide: Basic Information on How to Use the EQ-5D. 2009. URL: www.euroqol.org/fileadmin/user_upload/Documenten/PDF/User_Guide_v2_March_2009.pdf (accessed 14 May 2013).
131. Ware JE, Sherbourne CD. The MOS 36 item short-form health survery (SF-36). Med Care 1992;30:473-80. http://dx.doi.org/10.1097/00005650-199206000-00002
132. Ware JE, Gandek B, for the IQOLA project. Overview of the SF-36 health survey and the International Quality of Life Assessment (IQOLA) project. J Clin Epidemiol 1998;51:903-12. http://dx.doi.org/10.1016/S0895-4356(98)00081-X
133. Prescott-Clarke P, Primatesta P, editors. Health Survey for England 1996. London: The Stationery Office; 1998.
134. Thomas M, Goddard D, Hickman M, Hunter P. General Household Survey 1992. Office of Population Censuses and Surveys. London: HMSO; 1994.
135. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. Am Rev Respir Dis 1992;145:1321-7. http://dx.doi.org/10.1164/ajrccm/145.6.1321
136. Jones PW, Forde Y. St George’s Respiratory Questionnaire Manual. London: St George’s, University of London; 2009.
137. Jastrzebski D, Gumola A, Gawlik R, Kozielski J. Dyspnea and quality of life in patients with pulmonary fibrosis after six weeks of respiratory rehabilitation. J Physiol Pharmacol 2006;57:139-48.
138. HM Treasury. The Green Book: Appraisal and Evaluation in Central Government. URL: www.gov.uk/government/publications/the-green-book-appraisal-and-evaluation-in-central-government (accessed 14 March 2013).
139. Richeldi L, Ryerson CJ, Lee JS, Wolters PJ, Koth LL, Ley B, et al. Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis. Thorax 2012;67:407-11. http://dx.doi.org/10.1136/thoraxjnl-2011-201184
140. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183:788-824. http://dx.doi.org/10.1164/rccm.2009-040GL
141. Shulgina L, Cahn A, Chilvers E, Parfrey H, Clark A, Wilson E, et al. Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole. Thorax 2011;68:155-62. http://dx.doi.org/10.1136/thoraxjnl-2012-202403
142. Holland AE, Hill CJ, Conron M, Munro P, McDonald CF. Small changes in six-minute walk distance are important in diffuse parenchymal lung disease. Respir Med 2009;103:1430-5. http://dx.doi.org/10.1016/j.rmed.2009.04.024
143. Drummond MF, O’Brien B, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. 3rd edn. Oxford: Oxford University Press; 2005.
144. Briggs A, Claxton K, Sculpher M. Decision Modelling for Health Economic Evaluation. Oxford: Oxford University Press; 2006.
145. Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol 2012;12:9. http://dx.doi.org/10.1186/1471-2288-12-9
146. Latimer NR. Survival analysis for economic evaluations alongside clinical trials-extrapolation with patient-level data: inconsistencies, limitations, and a practical guide. Med Decis Making 2013;33:743-54. http://dx.doi.org/10.1177/0272989X12472398
147. Collard HR, King J, Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003;168:538-42. http://dx.doi.org/10.1164/rccm.200211-1311OC
148. Zappala CJ, Latsi PI, Nicholson AG, Colby TV, Cramer D, Renzoni EA, et al. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur Respir J 2010;35:830-5. http://dx.doi.org/10.1183/09031936.00155108
149. Miller DK, Homan SM. Determining transition probabilities: confusion and suggestions. Med Decis Making 1994;14:52-8. http://dx.doi.org/10.1177/0272989X9401400107
150. NHS Choices. Lung Transplant. NHS Choices; 2013. URL: www.nhs.uk/Conditions/Lung-transplant/ Pages/Introduction.aspx (accessed 14 June 2013).
151. Emin A, Rogers C, Taylor R, Barber K, van der Meulen J, Parameshwar J, et al. UK Cardiothoracic Transplant Audit: In Patients who Received a Transplant Between 1st July 1995 and 31st March 2011. London: RCS, Clinical Effectiveness Unit; 2011.
152. Christie JD, Edwards LB, Kucheryavaya AY, Benden C, Dobbels F, Kirk R, et al. The Registry of the International Society for Heart and Lung Transplantation: twenty-eighth Adult Lung and Heart-Lung Transplant Report-2011. J Heart Lung Transplant 2011;30:1104-22. http://dx.doi.org/10.1016/j.healun.2011.08.004
153. Office for National Statistics. Interim Life Tables, England and Wales, 2009-2011. London: Office for National Statistics; 2013. URL: www.ons.gov.uk/ons/rel/lifetables/interim-life-tables/2009-2011/stb-2009-2011.html (accessed 16 June 2013).
154. Anyanwu AC, McGuire A, Rogers CA, Murday AJ. Assessment of quality of life in lung transplantation using a simple generic tool. Thorax 2001;56:218-22. http://dx.doi.org/10.1136/thorax.56.3.218
155. Lloyd A, Price D, Brown R. The impact of asthma exacerbations on health-related quality of life in moderate to severe asthma patients in the UK. Prim Care Respir J 2007;16:22-7. http://dx.doi.org/10.3132/pcrj.2007.00002
156. Ara R, Brazier J. Deriving an algorithm to convert the eight mean SF-36 dimension scores into a mean EQ-5D preference-based score from published studies (where patient level data are not available). Value Health 2008;11:1131-43. http://dx.doi.org/10.1111/j.1524-4733.2008.00352.x
157. Longworth L, Rowen D. Mapping to obtain EQ-5D utility values for use in NICE health technology assessments. Value Health 2013;16:202-10. http://dx.doi.org/10.1016/j.jval.2012.10.010
158. Menn P, Weber N, Holle R. Health-related quality of life in patients with severe COPD hospitalized for exacerbations - comparing EQ-5D, SF-12 and SGRQ. Health Qual Life Outcomes 2010;8:39. http://dx.doi.org/10.1186/1477-7525-8-39
159. Department of Health. National Health Service England and Wales Electronic Drug Tariff May 2013. 2013. URL: www.ppa.org.uk/ppa/edt_intro.htm (accessed 14 June 2013).
160. Joint Formulary Committee. British National Formulary. 65 edn. London: BMJ Group and Pharmaceutical Press; 2013.
161. Department of Health. NHS Reference Costs 2011-2012. URL: www.gov.uk/government/publications/nhs-reference-costs-financial-year-2011-to-2012 (accessed 8 November 2012).
162. Department of Health. Costing Tool for Home Oxygen: Assessment and Review. URL: www.gov.uk/government/publications/commissioning-toolkit-for-respiratory-services (accessed 14 June 2013).
163. Department of Health. Service Specification: Home Oxygen Assessment and Review Service. www.gov.uk/government/publications/commissioning-toolkit-for-respiratory-services (accessed 14 June 2013).
164. Riley RD, Abrams KR, Lambert PC, Sutton AJ, Thompson JR. An evaluation of bivariate random-effects meta-analysis for the joint synthesis of two correlated outcomes. Stat Med 2007;26:78-97. http://dx.doi.org/10.1002/sim.2524
165. Riley RD, Abrams KR, Sutton AJ, Lambert PC, Thompson JR. Bivariate random-effects meta-analysis and the estimation of between-study correlation. BMC Med Res Methodol 2007;7:3. http://dx.doi.org/10.1186/1471-2288-7-3
166. Hawkins N, Scott DA. Cost-effectiveness analysis: discount the placebo at your peril. Med Decis Making 2010;30:536-43. http://dx.doi.org/10.1177/0272989X10362106
167. National Institute for Health and Care Excellence. Pirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis:. Manufacturer’s Single Technology Appraisal (STA) Submission to NICE. 2011. URL: www.nice.org.uk/nicemedia/live/13039/61701/61701.pdf (accessed 2 May 2013).
168. Ding Y, Fu H. Bayesian indirect and mixed treatment comparisons across longitudinal time points. Stat Med 2013;32:2613-28. http://dx.doi.org/10.1002/sim.5688
169. Wells AU. FVC as a primary end-point in IPF treatment trials: making a silk purse from a sow’s ear. Thorax 2012;0:1-2. http://dx.doi.org/10.1136/thoraxjnl-2012-202640
170. Flaherty KR, Mumford JA, Murray S, Kazerooni EA, Gross BH, Colby TV, et al. Prognostic implications of physiologic and radiologic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003;168:543-8. http://dx.doi.org/10.1164/rccm.200209-1112OC
171. King J, Safrin S, Starko KM, Brown KK, Noble PW, Raghu G, et al. Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis. Chest 2005;127:171-7. http://dx.doi.org/10.1378/chest.127.1.171
172. Latsi PI, du Bois RM, Nicholson AG, Colby TV, Bisirtzoglou D, Nikolakopoulou A, et al. Fibrotic idiopathic interstitial pneumonia. The prognostic value of longitudinal functional trends. Am J Respir Crit Care Med 2003;168:531-7. http://dx.doi.org/10.1164/rccm.200210-1245OC
173. du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med 2011;184:1382-9. http://dx.doi.org/10.1164/rccm.201105-0840OC
174. du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, et al. Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med 2011;183:1231-7. http://dx.doi.org/10.1164/rccm.201007-1179OC
175. du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011;184:459-66. http://dx.doi.org/10.1164/rccm.201011-1790OC
176. Swigris JJ, Kuschner WG, Jacobs SS, Wilson SR, Gould MK. Health-related quality of life in patients with idiopathic pulmonary fibrosis: a systematic review. Thorax 2005;60:588-94. http://dx.doi.org/10.1136/thx.2004.035220